eCommons@AKU
Woman and Child Health

Division of Woman and Child Health

6-28-2021

Direct maternal morbidity and the risk of pregnancy-related
deaths, stillbirths, and neonatal deaths in south Asia and subSaharan Africa: A population-based prospective cohort study in 8
countries
Imran Ahmed
Aga Khan University, imran.ahmed@aku.edu

Shabina Ariff
Aga Khan University, shabina.ariff@aku.edu

Zulfiqar Ahmed Bhutta
Aga Khan University, zulfiqar.bhutta@aku.edu

Muhammad Ilyas
Aga Khan University

Fyezah Jehan
Aga Khan University, fyezah.jehan@aku.edu

Follow
this
andfor
additional
works
at: https://ecommons.aku.edu/pakistan_fhs_mc_women_childhealth_wc
See next
page
additional
authors
Part of the Maternal and Child Health Commons, Pediatrics Commons, and the Women's Health
Commons

Recommended Citation
Ahmed, I., Ariff, S., Bhutta, Z. A., Ilyas, M., Jehan, F., Mehmood, U., Muhammad, K., Nisar, M. I., Soofi, S.,
Wasan, Y., Zaidi, A. (2021). Direct maternal morbidity and the risk of pregnancy-related deaths, stillbirths,
and neonatal deaths in south Asia and sub-Saharan Africa: A population-based prospective cohort study
in 8 countries. PLoS Medicine, 18(6), e1003644.
Available at: https://ecommons.aku.edu/pakistan_fhs_mc_women_childhealth_wc/182

Authors
Imran Ahmed, Shabina Ariff, Zulfiqar Ahmed Bhutta, Muhammad Ilyas, Fyezah Jehan, Usma Mehmood,
Karim Muhammad, Muhammad Imran Nisar, Sajid Bashir Soofi, Yaqub Wasan, and Anita K. M. Zaidi

This article is available at eCommons@AKU: https://ecommons.aku.edu/pakistan_fhs_mc_women_childhealth_wc/
182

RESEARCH ARTICLE

Direct maternal morbidity and the risk of
pregnancy-related deaths, stillbirths, and
neonatal deaths in South Asia and subSaharan Africa: A population-based
prospective cohort study in 8 countries
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111

OPEN ACCESS
Citation: Aftab F, Ahmed I, Ahmed S, Ali SM,
Amenga-Etego S, Ariff S, et al. (2021) Direct
maternal morbidity and the risk of pregnancyrelated deaths, stillbirths, and neonatal deaths in
South Asia and sub-Saharan Africa: A populationbased prospective cohort study in 8 countries.
PLoS Med 18(6): e1003644. https://doi.org/
10.1371/journal.pmed.1003644
Received: November 12, 2020
Accepted: May 4, 2021
Published: June 28, 2021
Copyright: © 2021 Aftab et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the manuscript and its Supporting
Information files.
Funding: The study was funded through a grant
from the Bill and Melinda Gates Foundation to the
World Health Organization. AWARD Number:
64438 (SY, RB from WHO). Website: https://www.
gatesfoundation.org/ The funder had no role in
study design, data collection and analysis, decision
to publish, or preparation of the manuscript.

Fahad Aftab ID1, Imran Ahmed2, Salahuddin Ahmed3, Said Mohammed Ali4,
Seeba Amenga-Etego5, Shabina Ariff2, Rajiv Bahl6*, Abdullah H. Baqui ID7,
Nazma Begum3, Zulfiqar A. Bhutta ID2, Godfrey Biemba8, Simon Cousens9, Vinita Das10,
Saikat Deb ID1,4, Usha Dhingra1, Arup Dutta1, Karen Edmond11, Fabian Esamai12, Amit
Kumar Ghosh ID13, Peter Gisore12, Caroline Grogan14, Davidson H. Hamer ID15,16,
Julie Herlihy15,17, Lisa Hurt ID18, Muhammad Ilyas ID19, Fyezah Jehan ID19, Mohammed
Hamad Juma4, Michel Kalonji20, Rasheda Khanam ID7, Betty R. Kirkwood ID9,
Aarti Kumar ID21, Alok Kumar22, Vishwajeet Kumar ID21, Alexander Manu23,24,
Irene Marete12, Usma Mehmood19, Nicole Minckas6, Shambhavi Mishra ID21,25, Dipak
K. Mitra ID26, Mamun Ibne Moin ID3, Karim Muhammad19, Sam Newton27, Serge Ngaima20,
Andre Nguwo20, Muhammad Imran Nisar ID19, John Otomba ID20, Mohammad
Abdul Quaiyum ID3, Sophie Sarrassat ID9, Sunil Sazawal ID1, Katherine E. Semrau ID14,28,29,
Caitlin Shannon ID30, Vinay Pratap Singh ID21, Sajid Soofi ID2,19, Seyi Soremekun ID9, Atifa
Mohammed Suleiman4, Venantius Sunday12, Thandassery R. Dilip ID6,
Antoinette Tshefu20, Yaqub Wasan ID2, Kojo Yeboah-Antwi ID15, Sachiyo Yoshida6*, Anita
K. Zaidi19, on behalf of The Alliance for Maternal and Newborn Health Improvement
(AMANHI) maternal morbidity study group‡

1 Centre for Public Health Kinetics (CPHK), New Delhi, Delhi, India, 2 Centre of Excellence in Women and
Child Health, The Aga Khan University, Karachi, Pakistan, 3 Projahnmo Research Foundation, Dhaka,
Bangladesh, 4 Public Health Laboratory-IdC, Pemba Island, Zanzibar, United Republic of Tanzania,
5 Kintampo Health Research Centre, Ghana Health Service, Kintampo, Ghana, 6 Department of Maternal
Newborn Child and Adolescent Health and Ageing, World Health Organization, Geneva, Switzerland,
7 Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore,
Maryland, United States of America, 8 National Health Research Authority, Ministry of Health, Lusaka,
Zambia, 9 London School of Hygiene & Tropical Medicine, London, United Kingdom, 10 Department of
Gynaecology & Obstetrics, King George’s Medical University, Lucknow, India, 11 King’s College London,
London, United Kingdom, 12 Department of Child Health and Pediatrics, Eldoret, Moi University, Kenya,
13 Government of India, New Delhi, India, 14 Ariadne Labs, Harvard T.H Chan School of Public Health,
Brigham and Women’s Hospital, Boston, Massachusetts, United States of America, 15 Department of Global
Health, Boston University School of Public Health, Boston, Massachusetts, United States of America,
16 Section of Infectious Diseases, Department of Medicine, Boston Medical Center, Boston, Massachusetts,
United States of America, 17 Department of Pediatrics, Boston University School of Medicine, Boston,
Massachusetts, United States of America, 18 CardiffAU
University
: Duetoduplicateaffiliations;
School of Medicine,thenumbersintheauthorbylineandaffiliati
Cardiff, United Kingdom,
19 Department of Paediatrics and Child Health, The Aga Khan University, Karachi, Pakistan, 20 Department
of Community Health, Kinshasa School of Public Health, Kinshasa, Demographic Republic of Congo,
21 Community Empowerment Lab, Shivgarh, India, 22 Government of Uttar Pradesh, India, 23 School of
Public Health, University of Ghana, Accra, Ghana, 24 Liverpool School of Tropical Medicine, Liverpool,
United Kingdom, 25 Department of Statistics, Lucknow University, Lucknow, India, 26 North South
University, Dhaka, Bangladesh, 27 Kwame Nkrumah University of Science & Technology, Kumasi Ghana,
28 Harvard Medical School, Department of Medicine, Boston, Massachusetts, United States of America,
29 Brigham and Women’s Hospital, Division of Global Health Equity, Boston, Massachusetts, United States
of America, 30 CARE USA, Atlanta, United States of America
‡ All authors contributed equally to the paper and all authors are listed in alphabetical order.
* bahlr@who.int (RB); yoshidas@who.int (SY)

PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003644 June 28, 2021

1 / 19

PLOS MEDICINE

Competing interests: We have read the journal’s
policy and the authors of this manuscript have the
following competing interests: ZAB is a member of
the Editorial Board of PLOS Medicine. Remaining
authors declared no competing interests.

A population-based prospective cohort study on direct maternal morbidities in eight countries

Abstract
Background

Maternal morbidity occurs several times more frequently than mortality, yet data on morbidity burden and its effect on maternal, foetal, and newborn outcomes are limited in low- and
Abbreviations: AU
AMANHI,
: Anabbreviationlisthasbeencompiledforthoseusedthroughoutthearticle:Pleaseverifythatallentriesarecorrect:
Alliance for Maternal and
Newborn Health Improvement; LMICs, low- and
middle-income countries. We aimed to generate prospective, reliable population-based
middle-income countries; OR, odds ratio.
data on the burden of major direct maternal morbidities in the antenatal, intrapartum, and
postnatal periods and its association with maternal, foetal, and neonatal death in South Asia
and sub-Saharan Africa.

Methods and findings
This is a prospective cohort study, conducted in 9 research sites in 8 countries of South Asia
and sub-Saharan Africa. We conducted population-based surveillance of women of reproductive age (15 to 49 years) to identify pregnancies. Pregnant women who gave consent were
include in the study and followed up to birth and 42 days postpartum from 2012 to 2015. We
used standard operating procedures, data collection tools, and training to harmonise study
implementation across sites. Three home visits during pregnancy and 2 home visits after birth
were conducted to collect maternal morbidity information and maternal, foetal, and newborn outcomes. We measured blood pressure and proteinuria to define hypertensive disorders of pregnancy and woman’s self-report to identify obstetric haemorrhage, pregnancy-related infection,
and prolonged or obstructed labour. Enrolled women whose pregnancy lasted at least 28
weeks or those who died during pregnancy were included in the analysis. We used meta-analysis to combine site-specific estimates of burden, and regression analysis combining all data
from all sites to examine associations between the maternal morbidities and adverse outcomes.
Among approximately 735,000 women of reproductive age in the study population, and
133,238 pregnancies during the study period, only 1.6% refused consent. Of these, 114,927
pregnancies had morbidity data collected at least once in both antenatal and in postnatal
period, and 114,050 of them were included in the analysis. Overall, 32.7% of included pregnancies had at least one major direct maternal morbidity; South Asia had almost double the
burden compared to sub-Saharan Africa (43.9%, 95% CI 27.8% to 60.0% in South Asia;
23.7%, 95% CI 19.8% to 27.6% in sub-Saharan Africa). Antepartum haemorrhage was
reported in 2.2% (95% CI 1.5% to 2.9%) pregnancies and severe postpartum in 1.7% (95%
CI 1.2% to 2.2%) pregnancies. Preeclampsia or eclampsia was reported in 1.4% (95% CI
0.9% to 2.0%) pregnancies, and gestational hypertension alone was reported in 7.4% (95%
CI 4.6% to 10.1%) pregnancies. Prolonged or obstructed labour was reported in about
11.1% (95% CI 5.4% to 16.8%) pregnancies. Clinical features of late third trimester antepartum infection were present in 9.1% (95% CI 5.6% to 12.6%) pregnancies and those of postpartum infection in 8.6% (95% CI 4.4% to 12.8%) pregnancies. There were 187 pregnancyrelated deaths per 100,000 births, 27 stillbirths per 1,000 births, and 28 neonatal deaths per
1,000 live births with variation by country and region. Direct maternal morbidities were associated with each of these outcomes.

Conclusions
Our findings imply that health programmes in sub-Saharan Africa and South Asia must
intensify their efforts to identify and treat maternal morbidities, which affected about one-
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third of all pregnancies and to prevent associated maternal and neonatal deaths and
stillbirths.

Trial registration
The study is not a clinical trial.

Author summary
Why was this study done?
• Estimates of severe direct maternal morbidity are largely based on hospital-based studies
with inconsistent definitions and varying selection criteria.
• Limited data are available from South Asia and sub-Saharan Africa, the 2 regions with
the highest maternal and newborn morbidity and mortality, where a larger proportion
of births occur at home.

What did the researchers do and find?
• We collected data on maternal morbidities from a cohort of women in the community
in multiple sites in sub-Saharan Africa and in South Asia.
• Out of a cohort of >114,000 women, we found that about 1 in 3 women suffer a maternal morbidity, which was notably higher than the previously reported data.
• We found that the prevalence of preeclampsia and eclampsia was about 1%, which was
lower than previously reported.
• About 11% of women reported having prolonged or obstructed labour, which was
somewhat higher than published estimates.
• The burden of pregnancy-related infection in postpartum period was higher in South
Asia than in sub-Saharan Africa.

• ThisAU
is the
: PleasenotethatthephrasetoourknowledgehasbeenaddedtothesentenceThisisthefirststudy;
first study, to our knowledge, to describe the burden of antepartum haemorto
rhage and late antepartum infection and to clearly demonstrate the association of direct
maternal morbidity with adverse pregnancy outcomes.

What do these findings mean?
• Higher burden of direct maternal morbidity and its association with adverse outcomes
highlights the need for improving health of women and mothers, including promotion
of preconception health and nutrition, and high-quality antepartum, intrapartum and
postpartum care.
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IntroductionAU : Pleaseconfirmthatallheadinglevelsarerepresentedcorrectly:
Safe motherhood programmes have largely focused on reduction of maternal mortality [1].
Inadequate attention has been paid to the morbidities that women experience during the pregnancy, intrapartum, and postpartum period. For every woman who dies of a maternal cause,
an estimated 20 to 30 women experience acute or chronic morbidity with substantial impact
on physical, psychological, social, and economic outcomes [2–5]. According to current WHO
estimates, approximately 15% of all pregnant women or about 20 million women annually
experience acute severe obstetric complications, including haemorrhage, obstructed or prolonged labour, preeclampsia or eclampsia, puerperal sepsis, and septic abortion [6]. These conditions affect the health of the foetus and newborn, in addition to the woman. For example,
the risk of perinatal mortality increases with placental abruption, ruptured uterus, systemic
infections/sepsis, preeclampsia, eclampsia, and severe anaemia [7]. Moreover, women whose
first pregnancy ends in stillbirth or is followed by death of the neonate is at increased risk of
experiencing the same outcome in her subsequent pregnancy [8].
Efforts to develop effective programmes and offer appropriate services to address maternal
morbidity in low- and middle-income countries (LMICs) have been undermined by the paucity of reliable data on maternal morbidity and its sequelae at the population level [9]. First,
maternal morbidity estimates have been constrained by the use of inconsistent definitions and
measurement methods of morbidities and their severity. A systematic literature review and
meta-analysis of severe maternal morbidity found its prevalence to vary between 0.05% and
15% of hospitalised women depending on the definition used [10]. Second, studies that aimed
to quantify the burden of maternal morbidity based their prevalence estimates on facilitybased data, which may not reflect the true burden at the population level particularly in population where a sizable proportion of deliveries occurring at home. The largest such study examined maternal morbidity in women attending health facilities in 29 countries from Africa,
Asia, Latin America, and the Middle East [11]. It was found that 7.3% of women had potentially life-threating conditions and that 1% developed a severe maternal outcome (defined as
maternal death or near miss). However, unbiased and accurate diagnosis of maternal morbidity in population-level studies becomes difficult under survey conditions without clinical
examination, laboratory reports, or medical records [12]. Point-in-time estimates from crosssectional surveys of maternal morbidity can be unreliable [13,14]. Not surprisingly, surveys
found that 70% of women or more report signs or symptoms of pregnancy-related complications [12,15,16]. Therefore, clear need exists to generate reliable population-based estimates of
maternal morbidity in LMICs using robust epidemiological methods.
The Alliance for Maternal and Newborn Health Improvement (AMANHI) study was
designed to provide these data from large community-based cohorts of pregnant and postpartum women in 9 sites in 8 countries across sub-Saharan Africa and South Asia. For 4 direct
maternal morbidities (obstetric haemorrhage, hypertensive disorders of pregnancy, pregnancy-related infection, and prolonged or obstructed labour), we aimed to (1) ascertain their
prevalence across sites and region and (2) examine their associations with pregnancy-related
death of women, stillbirth, and neonatal death.

Methods
Study overview
The AMANHI maternal morbidity study design and objectives have been described previously
(S1 Text) [17]. In brief, this population-based, cohort study of pregnant women was conducted
in Bangladesh (Sylhet), India (Uttar Pradesh), and Pakistan (Karachi and Matiari, both Sindh)
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in South Asia; and Democratic Republic of Congo (Equateur), Ghana (Brong Ahafo), Kenya
(Western Province), Tanzania (Pemba), and Zambia (Southern Province) in sub-Saharan
Africa. Data were collected from 2012 to 2015 and built on the platform of ongoing community-based research. The total population across sites was nearly 4 million with more than
735,000 women of reproductive age in the surveillance areas. These sites were predominantly
in rural settings and represented a range of maternal and newborn mortality.
Through a harmonisation process, a core protocol, core variable table, and schedule of visits
were agreed upon by WHO and site principal investigators. In all sites except Zambia, trained
fieldworkers made home visits to all women of reproductive age residing in the study area
every 2 to 3 months to obtain consent and interview them and ask them if they were pregnant,
and if they were pregnant, take consent for participation in the study, and collect baseline data.
During home visits, fieldworkers use a variety of methods to identify pregnant women. These
include direct disclosure by women or eliciting information on missed menstrual periods
from women’s LMPs. When unsure, women in Bangladesh, Pakistan (Karachi and Matiari,
Sindh), India (UP), and Tanzania (Pemba) had the option to request a urine pregnancy test to
confirm pregnancies. In Zambia, recruitment was facility based; this strategy was also population based as over 96% of women in the study area attend antenatal care clinics during pregnancy [18]. Pregnant women gave consent prior to enrolment in the cohort and to have their
pregnancy followed through the end of the postpartum period (after 42 days’ postpartum).
We conducted home visits at 5 time points: at 6 months’ pregnancy (24 to 28 weeks, or at
the time of identification of pregnancy, if later), at around 8 months’ pregnancy (32 to 37
weeks), at 9 months’ pregnancy (38 to 40 weeks’ pregnancy), in the first postpartum week, and
at the end of the postpartum period (at 7 to 11 postpartum weeks). These included blood pressure (Microlife WatchBP Home A BP3MX1-3, Widnau, Switzerland) and proteinuria (Uristix
by Siemens, Gujarat, India) measurements were performed at each visit. These study materials
were procured from a common source.
At enrolment, we collected data on baseline sociodemographic information and previous
medical and obstetric history. At home visits during pregnancy, data were collected on general
health, pregnancy-related morbidities, and care seeking; in addition, data were extracted from
the antenatal card, including the number and timing of visits, gestational age assessment, and
care and treatment received. At the first visit, morbidities were assessed from the beginning of
pregnancy; at subsequent visits, morbidities assessed since the previous visit. For each morbidity, we assessed the time of onset, severity, and any interventions received and where from. At
the first postpartum visit after birth, in addition to data on morbidities and care seeking, data
on labour, delivery, and immediate postpartum complications were captured for both the
mother and the neonate, as well as data on infant sex, birth weight, and feeding patterns were
collected.
Local and institutional ethics committees from all 9 sites approved the AMANHI study protocols. The Ethics Review Committee of WHO also approved the protocol (RPC 532).

Data management and quality assurance
Study staff underwent rigorous training for data collection. An independent team of study
supervisors conducted random spot checks of all workers once a month and monitored quality
of activities. Six monthly training sessions were held to standardise measurement of blood
pressure and proteinuria.
The 9 sites used standardised questionnaires with a defined set of core variables, and these
questionnaires were completed by interview, examination, anthropometry, or laboratory
analyses. Data managers within the sites conduct inter-database checks to reconcile and
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synchronise data from various forms using the woman’s unique study ID as the link. Every 3
months, sites transferred backup data to a dedicated server at WHO/MCA for external quality
control and storage. WHO undertook site monitoring, including observation of data collection, in all sites twice every year.

Outcomes and definitions
Women were included in the cohort analysis if they had at least one home visit during pregnancy
and one home visit after birth in the postnatal period or if they died in pregnancy. We excluded
pregnancies not reaching 28 weeks in the analyses to assess burden of maternal morbidities and
association of maternal morbidities with adverse outcomes. We assessed the following direct
maternal morbidities: obstetric haemorrhage (antepartum and postpartum), hypertensive disorders of pregnancy (preeclampsia and eclampsia, hypertension only), pregnancy-related infection
(late antepartum infection, postpartum infection), and prolonged or obstructed labour. We measured incidence and timing of stillbirths, neonatal deaths, and pregnancy-related deaths.
Antepartum haemorrhage was defined using women’s self-report of bleeding from vagina
occurring any time during pregnancy that wet her clothes (to exclude minor spotting).
Severe postpartum haemorrhage is usually defined based on greater than 1,000 ml blood
loss after birth of a baby. Measurement of blood loss after birth was not possible in our study.
In the community-based study especially for deliveries that take place at home, it was not possible to quantify the amount of blood lost. We therefore used pragmatic definitions and
defined severe postpartum haemorrhage as self-report of bleeding in the first week after birth
that resulted in loss of consciousness or required treatment by blood transfusion, hysterectomy, or other surgery.
We categorised women as having hypertensive disorders of pregnancy based on objective
measures of blood pressure and dipstick-measured proteinuria during home visits in pregnancy or after birth. In line with ACOG guidelines [19], we defined preeclampsia as diastolic
blood pressure �90 mm Hg and/or systolic blood pressure �140 mm Hg and proteinuria at
the same visit, and eclampsia as preeclampsia accompanied by convulsions at the same visit or
a subsequent visit.
We categorised women as having late antepartum or postpartum infection based on women’s self-report of having had fever or smelly discharge or pus pass from vagina. Late antepartum refers to the time from third trimester of pregnancy until delivery.
Women whose labour started �24 hours before delivery or who had cesarean delivery after
initiation of labour on account of a “big baby,” “small pelvis,” abnormal lie, or ruptured/imminent rupture of the uterus were classified as having had prolonged or obstructed labour.
If woman died and information on morbidity was not available by home visit, we obtained
information on maternal morbidity that woman had prior to death by verbal autopsy. The verbal autopsy was based on ICD-10 classification system [20].
Pregnancy-related death is a reflective of maternal deaths; however, the definition of pregnancy-related death includes all causes of deaths (obstetric and nonobstetric) including accidental or incidental causes during pregnancy till postpartum 42 days while maternal deaths
exclude deaths from such causes.
Stillbirth was defined as a foetal death after 28 weeks gestation. Antepartum stillbirth was
defined as foetal death occurring after 28 weeks of gestation and before the onset of labour. Intrapartum stillbirth was foetal deaths occurring after the onset of labour and before the delivery. Neonatal death was defined as the death of an infant during the first 28 days of life. Pregnancy-related
death was defined as the death of a woman while pregnant or within 42 days of termination of
pregnancy, irrespective of the duration and site of the pregnancy, from any cause.

PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003644 June 28, 2021

6 / 19

PLOS MEDICINE

A population-based prospective cohort study on direct maternal morbidities in eight countries

Statistical analysis
In our planning for the cohort, we expected to have 160,000 pregnancies in the study. This
sample size would have been sufficient to estimate a prevalence of maternal morbidity of 2%
with a relative precision of ±5% for each region (sub-Saharan Africa and South Asia). We
ended up with 114,927 pregnancies in the cohort. This shortfall in the sample means that we
can estimate a prevalence of maternal morbidity of 2% with relative precision ±6% for each
region (sub-Saharan Africa and South Asia).
We summarised baseline data on household, maternal, and infant characteristics using
means or medians for continuous data and proportions for categorical data. We summarised
morbidity prevalence and incidence using proportions.
We estimated the burden of each maternal morbidity (as a proportion of deliveries
affected), pregnancy-related deaths, stillbirth, and neonatal mortality for each site separately.
To obtain regional and global summary estimates of burden, we combined site-specific estimates using random effects meta-analysis. We then used logistic regression to investigate the
association between each maternal morbidity and the following outcomes: pregnancy-related
deaths, stillbirths, and neonatal deaths. Each maternal morbidity outcome was analysed in a
separate model. In each model, we adjusted for wealth quintile, educational attainment, maternal age, parity, multiple gestation, and site.
We used meta-analysis to combine site-specific estimates of burden (descriptive analyses),
while we used regression analysis combining all of the data from all sites to examine associations between the maternal morbidities (now the explanatory variable, not the outcome) and
pregnancy-related deaths, stillbirths, and neonatal deaths (the outcomes). In the latter analyses,
site was included as a covariate. All p-values were two sided. Analyses was done using Stata
14.0 statistical software package [21]. Missing data were reported in the footnotes of each result
table. We did not use any imputation methods for missing data.

Results
Study participants
Across the 9 sites, 114,927 pregnancies were identified, and 114,050 of them were included in
the analysis (Fig 1 and Table 1).
Women were mainly from rural, resource-limited environments. On average, women were
25 years old, 67% had attended school, and 71% had a previous livebirth. Approximately 9%
were adolescent mothers aged 15 to 19 years, and the proportion was high in 3 sites in subSaharan Africa, Zambia (24.5%), Kenya (19.0%), and DRC (17.3%) and was lowest in India
Shivgarh site (1.1%). One-fifth of women had a previous miscarriage (previous pregnancies
ended before 6 months), 9% had a previous stillbirth, and 3.3% had previous preterm birth
(previous pregnancies end more than 1 month before time). Approximately 74% had access to
an improved water source, 15% had access to toilet facility, and 9.4% lived in a household with
clean cooking fuel. However, wide variations in these sociodemographic characteristics were
observed by site and within the country (Table 1). For example, Karachi site was predominantly urban and peri-urban areas, while Matiari site was in rural areas.

Direct maternal morbidity
Overall, 32.7% of the pregnancies had at least one morbidity; with double the burden of morbidities in South Asia compared to sub-Saharan Africa (44.0% South Asia; 23.8% in sub-Saharan Africa) (Table 2). Women had 2 or more morbidities. For example, 35% of women with
obstructed labour had at least one other comorbidity; and 32% of women with hypertensive
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Fig 1. Flowchart of pregnant women enrolled in the AMANHI maternal morbidity study for all sites combined.
AMANHIAU
, Alliance
: AnabbreviationlisthasbeencompiledforthoseusedinFig1:Pleaseverifythatallentriesarecorrect:
for Maternal and Newborn Health Improvement; PRD, pregnancy-related death.
https://doi.org/10.1371/journal.pmed.1003644.g001

disorder had a comorbidity. Within the region, there were large variations in burden of
morbidity, particularly in late antepartum infection (5.6% in Bangladesh to 26.6% in Matiari
in South Asia) (Table A in S1 Table; S1–S8 Figs). Pooled data, which represent the average
across sites in the region, should be interpreted along with the range of morbidity burden
across sites.
About 2.2% (95% CI 1.5% to 2.9%) had antepartum haemorrhage, and 1.7% (95% CI 1.2%
to 2.2%) had severe postpartum haemorrhage. Overall, 1.4% (95% CI 0.9% to 2.0%) women
suffered from preeclampsia or eclampsia, and 7.4% (95% CI 4.6% to 10.1%) women had gestational hypertension alone. About 11.1% (95% CI 5.4% to 16.8%) women reported having prolonged or obstructed labour. Clinical features of late antepartum infection were present in
9.1% (95% CI 5.6% to 12.6%) and those of postpartum infection in 8.6% (95% CI 4.4% to
12.8%) women.
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Table 1. Baseline characteristics of pregnant women enrolled in AMANHI maternal morbidity study.
Characteristics
Pregnancies in the cohort (N)
Woman’s age, Median (IQR)

Total
114,927
25 (22 to
30)

Bangladesh
11,367

DRC

Ghana

7,031

12,834

24 (20 to 25 (20 to
27)
29)

27 (22 to
32)

India
Shivgarh
35,049

Kenya
8,528

25 (22 to 24 (20 to
27)
28)

Pakistan
Karachi
3,686

Pakistan
Matiari

Tanzania
Pemba

Zambia

12,59

16,854

6,985

26 (22 to 30) 29 (25 to 33)

27 (22 to 32)

24 (20 to
30)

Woman’s age in category, n (%)
15–19

10,312
(9.0)

1,945 (17.1)

1,174
(16.7)

1,490
(11.6)

397 (1.1)

1,616
(19.0)

299 (8.1)

220 (1.8)

1,469 (8.7)

1,702
(24.4)

20–29

73,368
(63.8)

7,408 (65.2)

3,673
(52.3)

6,839
(53.4)

29,580
(84.4)

5,039
(59.1)

2,185 (59.3)

6,309 (50.1)

8,985 (53.3)

3,350
(48.0)

30–39

27,610
(24.0)

1,906 (16.8)

1,445
(20.6)

3,970 4,852 (13.8)
(31.0)

1,561
(18.3)

1,126 (30.6)

5,626 (44.7)

5,471 (32.5)

1,653
(23.7)

88 (1.0)

73 (2.0)

435 (3.5)

928 (5.5)

249 (3.6)

106 (0.3) 224 (2.6)

3 (0.1)

3 (0.0)

1 (0.0)

31 (0.4)

971 (26.5)

2,329 (18.5)

11,973 (76.7)

6,113
(93.8)

>40

2,637
(2.3)

108 (1.0) 128 (1.8)

515 (4.0)

Missing

1,000
(0.9)

0 611 (8.7)

21 (0.2)

Woman attended school, n (%)

73,882
(66.8)

9,813 (89.5)

3,985
(71.2)

9,168
(71.6)

114 (0.3)

21,349
(61.7)

8,181
(99.4)

�
Women with previous livebirthPleasenotethattheindicators
y havebeeninterchangedinTable1andinitsfootnote:PerPLOSstyle;
indicatorsshouldbeinorderfrom
,n
80,161 7,724 (67.8) � and
5,478
9,399
20,864
6,120 2,762 (75.3) 9,830 (78.1) 13,099
(83.9)
4,885
(%)
(71.2)
(82.2)
(73.4)
(59.7)
(73.9)
(73.8)

Number of previous livebirths†,
Median (IQR)
Women with previous stillbirth� , n
(%)
Women with previous
miscarriage†, n (%)

2 (1 to 4)
7,292
(8.7)

2 (1 to 3)

3 (2 to
5)

2 (1 to 4)

2 (1 to 3) 2 (1 to 4)

3 (1 to 4)

3 (2 to 5)

4 (2 to 6)

3 (2 to 5)

916 (11.2) 465 (8.4)

919 (9.1)

1,822 (8.3) 213 (3.4)

196 (6.8)

1,429 (13.8)

1,061 (8)

271 (5.5)

2,295 4,303 (19.5) 403 (6.5)
(22.8)

792 (27.4)

2,726 (26.4)

3,003 (22.6)

237 (4.8)

16,249
(19.5)

1,704 (20.8)

786
(14.1)

Women with previous C section� ,
n (%)

3,076
(3.7)

231 (2.8)

59 (1.1)

525 (5.2)

816 (3.7)

89 (1.4)

132 (4.6)

875 (8.5)

294 (2.2)

55 (1.2)

Women with previous preterm
birth� , n (%)

2,772
(3.3)

288 (3.5) 310 (5.6)

213 (2.1)

719 (3.3) 274 (4.4)

84 (2.9)

301 (2.9)

413 (3.1)

170 (3.5)

Household access to improved
drinking water source‡, n (%)

82,754
(73.5)

5,481 (48.1) 229 (3.4)

10,539
(82.3)

33,640
(96.3)

2,492
(30.1)

2,221 (60.6) 12,402 (98.6)

13,934 (89.3)

1,816
(27.7)

Household access to toilet facility‡,
n (%)

16,960
(15.1)

4,153 (36.5)

87 (1.3)

320 (2.5)

658 (1.9)

14 (0.2)

3,036 (82.9)

5,478 (43.5)

2,959 (19)

255 (3.9)

Household using clean cooking
fuel#, n (%)

10,598
(9.4)

87 (0.8)

29 (0.4)

1,121
(8.8)

2,905 (8.3)

36 (0.4)

3,209 (87.5)

1,591 (12.6)

1,309 (8.4)

311 (4.7)

6,329
(5.7)

1,024 (9.1)

71 (1.1)

1,418
(11.3)

1,045 (3.0)

86 (1.3)

412 (11.4)

1,619 (13.2)

560 (3.4)

94 (1.5)

Birth by cesarean section
�

Denominator includes women who completed a pregnancy before enrolment.
†Among those who had previous livebirth(s).
‡Includes piped water, public tab, tube well, or rain water collection.

#Includes flush/pour flush toilet. Includes electricity, liquid petroleum gas, or kerosene.
https://doi.org/10.1371/journal.pmed.1003644.t001

The burden of pregnancy-related infection in South Asia was substantially higher than that
in sub-Saharan Africa (late antepartum infection 16.1% versus 3.5%, postpartum infection
16.3% versus 2.4%). The burden of obstetric haemorrhage was also higher in South Asia in
comparison to that in sub-Saharan Africa (antepartum haemorrhage 3.1% versus 1.5%, and
postpartum haemorrhage 2.6% versus 1.0%).
In contrast, the burden of hypertensive disorders of pregnancy was more similar in both
South Asia and sub-Saharan Africa (hypertension only 8.2% versus 6.7%, preeclampsia or
eclampsia 1.8% versus 1.2%). This was also the case with burden of prolonged or obstructed
labour (13.1% versus 9.5%).
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Table 2. Burden of direct maternal morbidities.
South Asia
Pregnancies that lasted 28 weeks or more,
�
or resulted in death, N
Obstetric haemorrhage
Antepartum haemorrhage; number, %, (95%
CI)†

sub-Saharan Africa

Overall

61,972

52,078

114,050

1,686, 3.1% (1.6% to
4.6%)

742, 1.5% (1% to 2%)

2,428, 2.2% (1.5% to
2.9%)

458, 1% (0.7% to
1.3%)

1,726, 1.7% (1.2% to
2.2%)

Severe postpartum haemorrhage; number, %, 1,268, 2.6% (1.5% to
3.7%)
(95% CI)‡
Hypertensive disorder of pregnancy
Hypertension only; number, %, (95% CI) #

5,228, 8.2% (3.3% to
13.1%)

3,777, 6.7% (3% to
10.1%)

9,005, 7.4% (4.6% to
10.1%)

Preeclampsia or eclampsia; number, %, (95%
CI)#

1,066, 1.8% (1.3% to
2.2%)

756, 1.2% (0.4% to
2%)

1,822, 1.4% (0.9% to
2%)

Late third trimester antepartum infection;
number, %, (95% CI)β

8,295, 16.1% (8.4%
to 23.8%)

1,875, 3.5% (1.4% to
5.7%)

10,170, 9.1% (5.6% to
12.6%)

Postpartum infection; number, %, (95%
CI)1

11,167, 16.3% (9.9%
to 22.6%)

1,170, 2.4% (1.4% to
3.5%)

12,337, 8.6% (4.4% to
12.8%)

Prolonged or obstructed labour; number,
%, (95% CI)"

12,636, 13.1% (0.6%
to 25.6%)

4,607, 9.5% (6.8% to
12.3%)

17,243, 11.1% (5.4%
to 16.8%)

Any of the above morbidities; number, %,
(95% CI)€

29,451, 44.0% (27.9% 11,758, 23.8% (19.8%
to 60.0%)
to 27.7%)

Pregnancy-related infection

�

A total of 183 women lost to follow-up, 92 in South Asia and 91 in sub-Saharan Africa.

†

Missing data for 101 deliveries in South Asia, 106 in sub-Saharan Africa.

41,209, 32.7% (22.2%
to 43.3%)

‡

Missing data for 796 deliveries in South Asia, 3,341 in sub-Saharan Africa.
Missing data for 305 deliveries in South Asia, 1,689 in sub-Saharan Africa.

#

β

Missing data for 828 deliveries in South Asia, 3,358 in sub-Saharan Africa.

1

Missing data for 795 deliveries in South Asia, 3,312 in sub-Saharan Africa.
Missing data for 834 deliveries in South Asia, 3,332 in sub-Saharan Africa.

"

€

Missing data for 1,478 deliveries in South Asia, 4,744 in sub-Saharan Africa.

https://doi.org/10.1371/journal.pmed.1003644.t002

Adverse pregnancy outcomes
Pregnancy-related deaths, neonatal mortality, and stillbirth rates were high in this population
(Tables B and C in S1 Table) [22].
The pregnancy-related death rate was 187 per 100,000 births with the major share of those
deaths happening around the time of labour and day of birth labour/delivery (65 per 100,000
births). We used total birth (all live and stillbirths) as the denominator.
Stillbirth rate was 27 deaths per 1,000 births with high regional variation (South Asia: 38;
sub-Saharan Africa: 18). Thirteen per 1,000 births occurred in the antepartum period, and 9
per 1,000 births occurred in the intrapartum period. The timings of death in the remaining 6
deaths per 1,000 births were indeterminate, and verbal autopsy was not done.
The neonatal mortality rate in this cohort was 28 per 1,000 livebirths, again, with wide variation by region (South Asia: 41; sub-Saharan Africa: 18). A large proportion (44%) of newborn
deaths occurred within the first 24 hours of life, and 30% occurred from day 1 to 6 after birth.

Direct maternal morbidities and pregnancy-related deaths

In an analysis adjusted for baseline characteristics, severe postpartum haemorrhage (oddsAU : Pleaseno
ratio (OR): 28.8, 95% CI 20.3 to 40.7), preeclampsia or eclampsia (OR: 9.13, 95% CI 6.10 to
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Table 3. Association of maternal morbidities with pregnancy-related deaths.
Maternal morbidity

Pregnancy-related deaths per 100,000 births (95% CI)

Adjusted OR� (95% CI)

p-value

†

Hypertensive disorder of pregnancy
None

187 (162 to 216)

1

Hypertension only

111 (60 to 207)

0.62 (0.33 to 1.19)

0.157

1,689 (1,190 to 2,392)

9.13 (6.1 to 13.7)

<0.001

Preeclampsia or eclampsia
Antepartum haemorrhage
No

193 (169 to 221)

1

Yes

699 (446 to 1,093)

2.80 (1.63 to 4.80)

<0.001

‡

Late antepartum maternal infection
No

174 (150 to 202)

1

Yes

127 (74 to 220)

0.55 (0.29 to 1.01)

0.057

Prolonged or obstructed labour#
No

175 (150 to 204)

1

Yes

158 (109 to 231)

0.77 (0.50 to 1.21)

No

118 (100 to 141)

1

Yes

3,240 (2,507 to 4,179)

28.8 (20.3 to 40.7)

0.255

Severe postpartum haemorrhageβ
<0.001

Postpartum maternal infection1
No

150 (128 to 177)

1

Yes

322 (237 to 439)

1.83 (1.245 to 2.69)

�

0.002

.Multivariable models included woman’s age, woman’s school attendance, previous livebirth, multiple births, wealth quintile, and site.

†

Missing data for 3 outcomes out of 232 pregnancy-related deaths (1.3%).
‡
Missing data for 47 outcomes (20.3%).
#

Missing data for 45 outcomes (19.4%).

β

Missing data for 48 outcomes (20.7%).
Missing data for 47 outcomes (20.3%).

1

https://doi.org/10.1371/journal.pmed.1003644.t003

13.7), and late antepartum maternal infection (OR: 2.80, 95% CI 1.63 to 4.80) increased the
risk of pregnancy-related death. Other direct maternal morbidities were not correlated with
pregnancy-related deaths (Table 3). Among socioeconomic and maternal characteristics, multiple births (a birth resulting in 2 or more children), previous history of C-section, wealth quintile, and older age (35 to 49 years of age) were most strongly associated with pregnancy-related
death (Table D in S1 Table). We looked into the result by region, and these results were similar
across regions.

Direct maternal morbidities and stillbirths
In a multivariate analysis, all measured direct maternal morbidities were associated with antepartum stillbirths. The strongest associations with antepartum stillbirths were with preeclampsia or
eclampsia (OR: 3.71, 2.99 to 4.61), severe postpartum haemorrhage (OR: 3.7, 2.98 to 4.60), and
antepartum haemorrhage (OR: 3.57, 2.96 to 4.32) (Table 4). Of socioeconomic and woman’s characteristics, multiple births, previous history of stillbirth and preterm birth, and mother’s age (35 to
49 years old) were strongly correlated with antepartum stillbirths (Table E in S1 Table).
Intrapartum stillbirths were most strongly associated with antepartum haemorrhage (OR:
2.86, 2.23 to 3.66), severe postpartum haemorrhage (OR: 2.66, 1.98 to 3.56), and prolonged or
obstructed labour (OR: 1.87, 1.62 to 2.16) (Table 4). Of socioeconomic and woman’s characteristics, multiple births, previous stillbirth, first pregnancy, and wealth quintile were strongly
associated with increased risk for intrapartum stillbirths (Table E in S1 Table).
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Table 4. Adjusted association of maternal morbidities with ASBs and ISBs.
ASBs
ASB per 1,000 births (95%
CI)

ISBs

�
Adjusted ORAU
: PleaseprovidesignificancefortheindicatorsinTable4andaddthemasfootnotesatth
(95%
p-value ISB per 1,000 births (95%
Adjusted OR (95% p-value
CI)
CI)
CI)

Maternal morbidity
Hypertensive disorder of
pregnancy†

3
None

14 (14 to 15)

1

Hypertension only

25 (21 to 28)

1.40 (1.20 to 1.63)

<0.001 11 (9 to 14)

11 (10 to 11)

1.01 (0.82 to 1.26)

1
0.885

Preeclampsia/eclampsia

61 (51 to 74)

3.71 (2.99 to 4.61)

<0.001 17 (12 to 25)

1.46 (0.99 to 2.15)

0.058

Antepartum haemorrhage
No

15 (14 to 16)

Yes 60 (51 to 70)

1
3.57 (2.96 to 4.32)

10 (10 to 11)
<0.001 33 (27 to 42)

1
2.86 (2.23 to 3.66)

<0.001

Late antepartum maternal
infection‡
No

15 (14 to 16)

1

Yes

29 (25 to 32)

1.58 (1.37 to 1.82)

10 (10 to 11)
<0.001 17 (15 to 20)

1
1.33 (1.11 to 1.59)

0.002

Prolonged or obstructed labour#
No

15 (14 to 16)

1

Yes

23 (20 to 25)

1.46 (1.29 to 1.67)

9 (9 to 10)
<0.001 19 (17 to 22)

1
1.87 (1.62 to 2.16)

<0.001

Severe postpartum haemorrhageβ
No

15 (14 to 16)

1

Yes

62 (51 to 75)

3.7 (2.98 to 4.60)

10 (10 to 11)
<0.001 31 (23 to 40)

1
2.66 (1.98 to 3.56)

<0.001

1

Postpartum maternal infection

No

14 (14 to 15)

1

Yes

29 (26 to 32)

1.70 (1.50 to 1.93)

10 (9 to 10)
<0.001 19 (17 to 22)

1
1.57 (1.35 to 1.83)

<0.001

ASBAU
, antepartum
: AnabbreviationlisthasbeencompiledforthoseusedinTable4:Pleaseverifythatallentriesarecorrect:
stillbirth; ISB, intrapartum stillbirths; OR, odds ratio.
https://doi.org/10.1371/journal.pmed.1003644.t004

Direct maternal morbidities and neonatal deaths
In a multivariate analysis, all measured direct maternal morbidities were associated with neonatal deaths. The morbidities strongly associated with neonatal death were antepartum haemorrhage (OR: 2.21, 95% CI: 1.87 to 2.63), severe postpartum haemorrhage (OR: 1.89, 1.53 to
2.33), and preeclampsia or eclampsia (OR: 1.76, 95% CI: 1.41 to 2.20) (Table 5). Socioeconomic and maternal characteristics strongly associated with increased risk of neonatal deaths
were multiple births, previous history of stillbirth, first pregnancy, wealth quintile, and previous history of preterm birth (Table F in S1 Table).

Discussion
This large prospective cohort study conducted in about 114,000 pregnant women in South
Asia and sub-Saharan Africa shows that a third of women suffer from a direct maternal morbidity. The proportion of women with direct maternal morbidity was greater in South Asia
(44%) than in sub-Saharan Africa (24%), largely because of a greater prevalence of pregnancyrelated infections. Pregnancy-related death, neonatal mortality, and stillbirth rates were similar
to the study based on larger AMANHI mortality study [22]. The study clearly demonstrated
that direct maternal morbidity is associated with pregnancy-related deaths, stillbirths, and neonatal deaths.
A review of available systematic reviews reported 27 million morbid episodes from 5 main
direct obstetric causes, among 210 million pregnancies (13%) globally in 2015 [23]. Another
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Table 5. Adjusted association of maternal morbidities with NNDs.
NNDs
Maternal morbidity

NND

Adjusted OR�

per 1,000 livebirth

(95% CI)

p-value

(95% CI)
Hypertensive disorder†
None

30 (29 to 31)

1

Hypertension only

34 (31 to 38)

1.07 (0.94 to 1.22)

0.295

Preeclampsia/eclampsia

57 (47 to 69)

1.76 (1.41 to 2.20)

<0.001

Antepartum haemorrhage
No

29 (28 to 30)

1

Yes

73 (63 to 85)

2.21 (1.87 to 2.63)

<0.001

‡

Late antepartum maternal infection

No

27 (26 to 29)

1

Yes

53 (48 to 57)

1.52 (1.38 to 1.69)

<0.001

Prolonged or obstructed labour#
No

27 (26 to 28)

1

Yes

44 (41 to 47)

1.49 (0.35 to 1.63)

No

29 (28 to 30)

1

Yes

67 (56 to 81)

1.89 (1.53 to 2.33)

No

27 (26 to 28)

1

Yes

55 (51 to 59)

1.63 (1.48 to 1.79)

<0.001

Severe postpartum haemorrhageβ
<0.001

Postpartum maternal infection1

�

Multivariable models included, woman’s age, woman’s school attendance, previous livebirth, multiple births, wealth quintile, and site.

†

Missing data for 36 out of 3,343 NND (1.1%).

<0.001

‡
#

Missing data for 125 outcomes (3.7%).
Missing data for 129 outcomes (3.9%).

β

Missing data for 120 outcomes (3.6%).

1

Missing data for 120 outcomes (3.6%).
NNDAU
, neonatal
: AnabbreviationlisthasbeencompiledforthoseusedinTable5:Pleaseverifythatallentriesarecorrect:
death; OR, odds ratio.
https://doi.org/10.1371/journal.pmed.1003644.t005

major previous source of maternal morbidity data was the WHO multicountry survey, which
provided data from a third of a million women who attended district or tertiary hospitals in 29
LMICs [24]. Most of the previous data are from hospital-based studies, and studies have lacked
common definitions and standard identification criteria [25]. The major strengths of our
study are its prospective, population-based, cohort design, large sample size, and harmonised
data collection schedule and tools, training, implementation, and common definitions of
maternal morbidity at all the study sites. We identified all pregnant women in the study population using 1 to 3 monthly reproductive surveillance sweeps and prospectively followed up
95% of all reported pregnancies to the end of the postpartum period; thus, possibility of recall
and reporting bias was minimised. Our study was conducted in South Asia and sub-Saharan
Africa, the 2 regions with the highest burden of maternal and newborn mortality and morbidity and with the greatest paucity of data.
We included pregnancies that lasted at least for 28 weeks (or those of shorter duration that
resulted in death of the pregnant woman or a live-born neonate) in the study because of the following reasons. Maternal morbidity information was collected for the first time at 24 to 28 weeks
because most women present quite late during pregnancy. However, if a pregnant woman died at
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any gestation, or a live-born neonate with <28 weeks gestation died, information on morbidity
was collected by a verbal autopsy. We felt that it was not appropriate to present morbidity information for the remaining pregnancies that ended <28 weeks (considered to be miscarriages or
abortions based on WHO definition) because our study was likely to miss most of these cases
because of late reporting of pregnancy and would thus be a serious underreporting.
Our study has some limitations. Even though the sample size was large, population of a geographically limited site per country was included, and it is unlikely that the study sites are representative of the entire country and region. Second, morbidity information was collected only
at 5 contacts during pregnancy and postpartum period, and not all enrolled women had all
these contacts, which could have resulted in some underestimation of morbidity. Third, we
did not collect information on indirect maternal morbidities such as anaemia or gestational
diabetes. Fourth, as we only presented data on infections in the late antenatal period, we are
likely to have underestimated the total burden of pregnancy-related infections, and it was not
possible to examine the aetiology of infections using these self-reported data. Fifth, although
all the visits during pregnancy and after birth were all conducted at home/in the community
in Zambia site, there may be possibility that the different enrolment strategy in Zambia may
have led to an underestimate of pregnancy-related deaths, stillbirths, and neonatal deaths in
that site. Finally, except hypertensive disorders of pregnancy for which blood pressure was
measured and urine examination done at each visit, all other morbidities were based on selfreporting of symptoms and signs by the pregnant women.
This design proposed by the reviewer is appropriate for settings with well-established health
systems that are universally accessible, but any such validation is likely to be incomplete in settings where most women do not seek care for their morbidity and biased towards an identification of the severest morbidities only. We were seeking to derive community-based estimates
of morbidity in this study. In addition, even in a setting where clinical records are accessible,
the information that could be retrieved is likely to be poor quality. Therefore, while we did
consider collecting facility-based information in the study for triangulation purposes, this was
not found to be feasible. Instead, we focused on improving the quality of the data that we
could collect in the community, using periodic observation of blood pressure and proteinuria
for our preeclampsia estimations for example. However, other morbidities (e.g., haemorrhage,
infections, and obstructed labour) were not amenable to such measurements, and, therefore,
self-reporting was deemed to be most appropriate strategy for these settings. There is a possibility that differential understanding of questions could have contributed to variations in morbidity estimates across countries and regions, in addition to the true epidemiologic
differences. However, rigorous training of field workers and the monthly random spot checks
limit the scope of such potential bias.
We found a similar incidence of hypertensive disorders of pregnancy in South Asia (8.2%)
and sub-Saharan Africa (6.7%). Most of these women had gestational hypertension, while
1.4% had preeclampsia or eclampsia (1.8% in South Asia and 1.2% in sub-Saharan Africa). Previous study and a review have reported that a higher proportion of pregnant women have preeclampsia (2.3%) and eclampsia (0.5%) [23,24]. This difference may be explained by
population-based nature of our cohort, because hospital-based data tend to have a higher prevalence of severe morbidity. Incidence of hypertensive disorders of pregnancy in our study was
similar to the published rate of 6% to 8% in aAU
community-based
: PleaseconfirmthattheeditstothesentenceIncidenceofhy
study in less-developed settings [26]. The same study, however, reported higher incidence of preeclampsia or eclampsia
(2% to 4%). This rate was higher than ours by 2-fold. This could be because our definition of
preeclampsia was based on hypertension and presence of proteinuria only, whereas Magee’s
definition was gestational hypertension plus proteinuria or a preeclampsia-defining signs and
symptoms (headache, visual symptoms, chest pain, etc.).
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Two previous systematic reviews reported that 1.7% and 2.8% women had severe postpartum haemorrhage, respectively [27,28]. The corresponding proportion in our study was 1.7%
(2.6% in South Asia and 1.0% in sub-Saharan Africa). Thus, our findings are similar despite
using a different definition of severe postpartum haemorrhage (haemorrhage accompanied by
loss of consciousness, or the need for blood transfusion or surgery) rather than the previously
used 1,000 ml blood loss. Research indicated that women are unable to accurately report on
the amount of blood loss. We also found that about 2.2% pregnant women (3.1% in South Asia
and 1.5% in sub-Saharan Africa) have antepartum haemorrhage, but we could not find any
systematic reviews or global estimates for this morbidity. We found one systematic review on
placenta previa showing main conditions responsible for antepartum haemorrhage, which is
consistent with our findings. This review showed that the prevalence was 1.2% of pregnancies
in Asia and 0.3% of pregnancies in sub-Saharan Africa [29].
We observed that a large proportion of women had clinically suspected pregnancy-related
infection, both in late third trimester (16.1% in South Asia and 3.5% in sub-Saharan Africa) as
well as in the postpartum period (16.3% in South Asia and 2.4% in sub-Saharan Africa). A published systematic review showed pooled maternal infection estimates of approximately 4% in
labour and about 3.5% in postpartum period [30]. The overwhelming majority of studies
included in this review were from high-income country settings, and the diagnosis was made
at health facilities. Another review based on review of hospital and community studies showed
that global estimate of postpartum sepsis was 4.4% [31]. The higher rate of antepartum and
postpartum infection in South Asia observed in our study may be related to higher risk of
infections in high-density population settings. However, we used self-reported fever and vaginal discharge as a basis of ascertaining infections and therefore cannot rule out the possibility
of overreporting by women in South Asia. Our aim was to derive community-based estimates
of maternal infections from women’s self-reporting. However, large intraregion variations in
the burden of late antepartum infections and postpartum infections particularly in South Asia
could imply that self-reported infections signs were challenging to collect. Overcrowding,
poorer hygiene, lower education, and higher rates of malnutrition in South Asian sites could
also be potential explanatory factors. The high burden of pregnancy-related infection may be
an important risk factor for stillbirth, preterm birth, and early neonatal sepsis. The remarkable
difference in infection rates between Asia and Africa should be explored further in future
studies.
In this study, 11.1% women reported prolonged or obstructed labour, 13.1% in South Asia,
and 9.5% in sub-Saharan Africa. These proportions, particularly in South Asia, were somewhat
higher than those reported (8.7%) [32–33] A high proportion of home deliveries and poor
quality of childbirth care in facilities could have contributed to the high rates that we observed.
It may also be due to difficulty of women knowing exactly when labour started.
The intraregional and interregional variations in the burden of direct maternal morbidity
in our study could be because of epidemiological and health system contexts of different
sites. Overcrowding, sanitation, literacy, and fertility were different across sites (Table 1) Quality of care during antepartum, intrapartum, and postpartum periods was also likely to quite
different across study sites. A number of sociodemographic and health variables were significant risk factors for pregnancy-related deaths, stillbirths, and neonatal deaths (Tables C–E in
S1 Table).
Relatively higher proportion of missing data was observed in pregnancy-related deaths than
in stillbirths or in neonatal deaths. This is primarily because it is a rare outcome, and it was not
possible to obtain any data on maternal morbidities if verbal autopsies were not conducted.
This study has important implications for public health programmes that aim to improve
maternal, foetal, and newborn health and survival. First, the high burden of morbidity and
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clear evidence of its association with pregnancy-related deaths, stillbirth, and neonatal deaths
highlight the need for improving health of women and mothers. This includes promotion of
preconception health and high-quality antepartum, intrapartum, and postpartum care. Second, antenatal care models with a minimum of 8 contacts recommended by WHO will help in
early identification and treatment of morbidity. In addition to improving the health system,
there is a need to improve community-based interventions to prevent, identify, and refer pregnant women with morbidities to help address ongoing challenges in appropriate care for these
women. Second, the quantitative estimates of disease burden can be used to more efficiently
plan health services. This implies having adequate infrastructure, strong referral network,
health worker, and medical supplies to treat common morbidities. Finally, given the limitations of the current global and regional estimates of maternal morbidity, it is important that
our estimates from population-based prospective cohorts are used to improve them. We
believe that implementation of effective strategies for prevention and management of maternal
morbidity will help women, foetuses, and newborns survive and thrive and accelerate progress
towards achieving Sustainable Development Goals.
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